Why Investors Are Cheering the Results of Novo’s Victoza Trials


Mar. 8 2016, Updated 12:37 p.m. ET

Update on Novo’s Victoza trials

On March 4, 2016, Novo Nordisk (NVO) announced the top-line results of its Leader trial. The trial was initiated in September 2010 to evaluate cardiovascular safety and efficacy of Victoza. For detailed information on Victoza, please refer to, How Did Novo’s Victoza Become a Leading Diabetes Drug?

According to top-line results, Victoza proved to be superior to existing treatments in reducing cardiovascular risks in patients with type two diabetes. The safety was evaluated over a period of five years in diabetic patients who were at high risk of major adverse cardiovascular events. Eli Lilly’s (LLY) Jardiance was the first approved drug of the kind.

Article continues below advertisement

Trial results

The trial included 9,340 patients with type two diabetes. The graph above highlights the inclusion criteria for the study. Patients were over 50 years of age and were suffering from cardiovascular disease along with type two diabetes. Patients above 60 years of age had multiple cardiovascular risk factors.

Type two diabetes is the most common type of diabetes, and it accounts for 90%–95% of the total diabetes cases. Usually, type two diabetes is accompanied by obesity, high blood pressure, and high cholesterol levels. The presence of these ailments increases the risk of heart disease by two to four times in such patients. Drugs like Victoza improve the care of diabetic patients.

In the diabetes space, Novo competes with Merck (MRK), AstraZeneca (AZN), Eli Lilly, and Sanofi (SNY). The success of Novo’s trial may boost Victoza sales.

What is HbA1c?

The Leader study involved diabetic patients whose HbA1c was 7.0% or above. Normal levels for HbA1c are below 5.7%, whereas levels above 6.5% imply diabetes. As per the National Institute of Diabetes and Digestive and Kidney Diseases, “The A1C test is a blood test that provides information about a person’s average levels of blood glucose, also called blood sugar, over the past 3 months. The A1C test is sometimes called the hemoglobin A1c, HbA1c, or glycohemoglobin test. The A1C test is the primary test used for diabetes management and diabetes research.”

To diversify the risk of investing directly in Novo Nordisk, investors can look for options such as the PowerShares International Dividend Achievers Portfolio (PID). PID invests 0.49% of its total holdings in Novo Nordisk.


More From Market Realist

  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • Bitski art and logo
    Company & Industry Overviews
    NFT Platform Provider Bitski Isn’t Publicly Traded
  • who are palantir customers
    Company & Industry Overviews
    Palantir Customers Are Large Defense and Commercial Institutions
  • Grain trucks waiting to be loaded and Archer Daniels logo
    Company & Industry Overviews
    Archer Daniels Stock Is a Buy Amid Price Dip and Big Announcement
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.